Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis

(2013) Anat Achiron et al.   DISEASE MARKERS

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

(2010) F. Morschhauser et al.   ANNALS OF ONCOLOGY

A Genomic Approach to Human Autoimmune Diseases

(2010) Virginia Pascual et al.   Annual Review of Immunology

Clinical Effect of Neutralizing Antibodies to Interferon Beta That Persist Long After Cessation of Therapy for Multiple Sclerosis

(2010) Laura F. van der Voort   ARCHIVES OF NEUROLOGY

The blood–brain barrier, chemokines and multiple sclerosis

(2010) David W. Holman et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Overlapping and distinct mechanisms of action of multiple sclerosis therapies

(2010) J.J. Graber et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Disease protection and interleukin-10 induction by endogenous interferon-β in multiple sclerosis?

(2010) D. Hesse et al.   EUROPEAN JOURNAL OF NEUROLOGY

Molecular oracles for multiple sclerosis therapy

(2010) Hartmut Wekerle et al.   NATURE MEDICINE

T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis

(2010) Robert C Axtell et al.   NATURE MEDICINE

Breakthrough disease during interferon-  therapy in MS: No signs of impaired biologic response

(2010) D. Hesse et al.   NEUROLOGY

Cross-sectional study assessing long-term safety of interferon- -1b for relapsing-remitting MS

(2010) A. T. Reder et al.   NEUROLOGY

Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-β-1b treatment in relapsing remitting MS

(2010) Robert H Goertsches et al.   PHARMACOGENOMICS

Novel Approaches to Detect Serum Biomarkers for Clinical Response to Interferon-β Treatment in Multiple Sclerosis

(2010) Kaushal S. Gandhi et al.   PLoS One

Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis

(2010) Orhan Aktas et al.   TRENDS IN NEUROSCIENCES

T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β

(2009) Luca Durelli et al.   ANNALS OF NEUROLOGY

Systems biology and its application to the understanding of neurological diseases

(2009) Pablo Villoslada et al.   ANNALS OF NEUROLOGY

Genome-wide Scan of 500 000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple Sclerosis

(2009) Manuel Comabella et al.   ARCHIVES OF NEUROLOGY

Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells

(2009) Michael Gurevich et al.   BMC Medical Genomics

A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis

(2009) M. Comabella et al.   BRAIN

ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis

(2009) S. Cotte et al.   BRAIN

Identification of new sensitive biomarkers for thein vivoresponse to interferon-β treatment in multiple sclerosis using DNA-array evaluation

(2009) F. Sellebjerg et al.   EUROPEAN JOURNAL OF NEUROLOGY

IFN-  Inhibits Human Th17 Cell Differentiation

(2009) V. S. Ramgolam et al.   JOURNAL OF IMMUNOLOGY

Role of the innate immune system in the pathogenesis of multiple sclerosis

(2009) Roopali Gandhi et al.   JOURNAL OF NEUROIMMUNOLOGY

Monitoring of multiple sclerosis immunotherapy

(2009) Robert H. Goertsches et al.   JOURNAL OF NEUROLOGY

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

(2009) Richard A Rudick et al.   LANCET NEUROLOGY

Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit

(2009) WM Carroll   Multiple Sclerosis Journal

MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis

(2009) Changsheng Du et al.   NATURE IMMUNOLOGY

Predicting responders to therapies for multiple sclerosis

(2009) Jordi Río et al.   Nature Reviews Neurology

Absence of MxA induction by interferon   in patients with MS reflects complete loss of bioactivity

(2009) D. Hesse et al.   NEUROLOGY

The mechanism of action of glatiramer acetate treatment in multiple sclerosis

(2009) M. K. Racke et al.   NEUROLOGY

Interferon-  mechanisms of action in multiple sclerosis

(2009) S. Dhib-Jalbut et al.   NEUROLOGY

United Europeans for development of pharmacogenomics in multiple sclerosis network

(2009) Koen Vandenbroeck et al.   PHARMACOGENOMICS

Genetic polymorphisms, their allele combinations and IFN-β treatment response in Irish multiple sclerosis patients

(2009) Catherine O’Doherty et al.   PHARMACOGENOMICS

Longitudinal system-based analysis of transcriptional responses to type I interferons

(2009) D. J. Pappas et al.   PHYSIOLOGICAL GENOMICS

Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis

(2008) Esther Byun et al.   ARCHIVES OF NEUROLOGY

Interferon-β increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity

(2008) M. Krumbholz et al.   BRAIN

BAFF is a Biological Response Marker to IFN-β Treatment in Multiple Sclerosis

(2008) Kaushal S. Gandhi et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

IFN-β1b Induces Transient and Variable Gene Expression in Relapsing-Remitting Multiple Sclerosis Patients Independent of Neutralizing Antibodies or Changes in IFN Receptor RNA Expression

(2008) Anthony T. Reder et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Genomic effects of once-weekly, intramuscular interferon-β1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients

(2008) Bianca Weinstock-Guttman et al.   JOURNAL OF NEUROIMMUNOLOGY

IFN-β-regulated genes show abnormal expression in therapy-naïve relapsing–remitting MS mononuclear cells: Gene expression analysis employing all reported protein–protein interactions

(2008) Ken D. Yamaguchi et al.   JOURNAL OF NEUROIMMUNOLOGY

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET

Gene expression analysis of interferon-β treatment in multiple sclerosis

(2008) F Sellebjerg et al.   Multiple Sclerosis Journal

The genetics of multiple sclerosis: SNPs to pathways to pathogenesis

(2008) Jorge R. Oksenberg et al.   NATURE REVIEWS GENETICS

Pharmacogenomics of IFN-β in multiple sclerosis: towards a personalized medicine approach

(2008) Saskia Vosslamber et al.   PHARMACOGENOMICS

Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients

(2008) Lisa G. M. van Baarsen et al.   PLoS One

A Global View of Gene Activity and Alternative Splicing by Deep Sequencing of the Human Transcriptome

(2008) M. Sultan et al.   SCIENCE

Interleukin-17: A novel inflammatory cytokine that bridges innate and adaptive immunity

(2007) Jeffrey et al.   Frontiers in Bioscience-Landmark